DOI QR코드

DOI QR Code

The 2017 Update of the Clinical Guidelines for ST-Segment Elevation Myocardial Infarction of the European Society of Cardiology

2017 유럽심장학회 ST분절 상승형 심근경색증 진료지침의 새로운 점

  • Bae, Jang-Whan (Division of Cardiology, Department of Internal Medicine, Chungbuk National University College of Medicine)
  • 배장환 (충북대학교 의과대학 의학과 내과학교실)
  • Published : 2018.02.01

Abstract

The 2017 Clinical Guidelines for ST-segment elevation myocardial infarction of the European Society of Cardiology updated many important aspects of the pre-hospital phase, the selection of a reperfusion strategy, interventional and pharmacological treatment, and patient quality assessment. The principal changes are a clear definition of the first medical contact, elimination of the door-to-balloon time from consideration, recommended radial access intervention, a recommendation that drug-eluting stents should be preferred to bare metal stents, recommended complete revascularization during hospitalization, and early discharge of selected patients. Routine manual thrombus aspiration and oxygen supplementation for patients who are not hypoxemic are now discouraged.

Keywords

References

  1. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119-177. https://doi.org/10.1093/eurheartj/ehx393
  2. Widimsky P, Rohac F, Stasek J, et al. Primary angioplasty in acute myocardial infarction with right bundle branch block: should new onset right bundle branch block be added to future guidelines as an indication for reperfusion therapy? Eur Heart J 2012;33:86-95. https://doi.org/10.1093/eurheartj/ehr291
  3. Yan AT, Yan RT, Kennelly BM, et al. Relationship of ST elevation in lead aVR with angiographic findings and outcome in non-ST elevation acute coronary syndromes. Am Heart J 2007;154:71-78. https://doi.org/10.1016/j.ahj.2007.03.037
  4. Stub D, Smith K, Bernard S, et al. Air versus oxygen in ST-segment elevation myocardial infarction. Circulation 2015;131:2143-2150. https://doi.org/10.1161/CIRCULATIONAHA.114.014494
  5. Hofmann R, James SK, Svensson L, et al. DETermination of the role of OXygen in suspected acute myocardial infarction trial. Am Heart J 2014;167:322-328. https://doi.org/10.1016/j.ahj.2013.09.022
  6. Kern KB, Rahman O. Emergent percutaneous coronary intervention for resuscitated victims of out-of-hospital cardiac arrest. Catheter Cardiovasc Interv 2010;75:616-624.
  7. Garcia-Tejada J, Jurado-Roman A, Rodriguez J, et al. Postresuscitation electrocardiograms, acute coronary findings and in-hospital prognosis of survivors of out-of-hospital cardiac arrest. Resuscitation 2014;85:1245-1250. https://doi.org/10.1016/j.resuscitation.2014.06.001
  8. Vaahersalo J, Hiltunen P, Tiainen M, et al. Therapeutic hypothermia after out-of-hospital cardiac arrest in Finnish intensive care units: the FINNRESUSCI study. Intensive Care Med 2013;39:826-837. https://doi.org/10.1007/s00134-013-2868-1
  9. Karrowni W, Vyas A, Giacomino B, et al. Radial versus femoral access for primary percutaneous interventions in ST-segment elevation myocardial infarction patients: a metaanalysis of randomized controlled trials. JACC Cardiovasc Interv 2013;6:814-823. https://doi.org/10.1016/j.jcin.2013.04.010
  10. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2013;62:496-504. https://doi.org/10.1016/j.jacc.2013.05.022
  11. Frobert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 2013;369:1587-1597. https://doi.org/10.1056/NEJMoa1308789
  12. Jolly SS, Cairns JA, Yusuf S, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 2015;372:1389-1398. https://doi.org/10.1056/NEJMoa1415098
  13. Kelb.oll, Hofsten DE, Kober L, et al. Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial. Lancet 2016;387:2199-2206. https://doi.org/10.1016/S0140-6736(16)30072-1
  14. Elgendy IY, Mahmoud AN, Kumbhani DJ, Bhatt DL, Bavry AA. Complete or culprit-only revascularization for patients with multivessel coronary artery disease undergoing percutaneous coronary intervention: a pairwise and network meta-analysis of randomized trials. JACC Cardiovasc Interv 2017;10:315-324. https://doi.org/10.1016/j.jcin.2016.11.047
  15. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015. https://doi.org/10.1056/NEJMoa0706482
  16. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057. https://doi.org/10.1056/NEJMoa0904327
  17. Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015;373:997-1009. https://doi.org/10.1056/NEJMoa1507854
  18. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295:1519-1530. https://doi.org/10.1001/jama.295.13.joc60038
  19. Azzalini L, Sole E, Sans J, et al. Feasibility and safety of an early discharge strategy after low-risk acute myocardial infarction treated with primary percutaneous coronary intervention: the EDAMI pilot trial. Cardiology 2015;130:120-129. https://doi.org/10.1159/000368890
  20. Jones DA, Rathod KS, Howard JP, et al. Safety and feasibility of hospital discharge 2 days following primary percutaneous intervention for ST-segment elevation myocardial infarction. Heart 2012;98:1722-1727. https://doi.org/10.1136/heartjnl-2012-302414
  21. Estevez-Loureiro R, Calvireiro RRathodVazquez JM, et al. Safety and feasibility of returning patients early to their originating centers after transfer for primary percutaneous coronary intervention. Rev Esp Cardiol 2009;62:1356-1364. https://doi.org/10.1016/S0300-8932(09)73120-3
  22. Costa F, Tijssen JG, Ariotti S, et al. Incremental value of the CRUSADE, ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy. J Am Heart Assoc 2015;4:e002524.
  23. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-225. https://doi.org/10.1093/eurheartj/ehi115
  24. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669-685. https://doi.org/10.1016/S0140-6736(95)90865-X
  25. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906. https://doi.org/10.1056/NEJMoa032292
  26. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435. https://doi.org/10.1056/NEJMoa050461
  27. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-1722. https://doi.org/10.1056/NEJMoa1615664
  28. Authors/Task Force Members; Catapano AL, Graham I, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016;253:281-344. https://doi.org/10.1016/j.atherosclerosis.2016.08.018
  29. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-2397. https://doi.org/10.1056/NEJMoa1410489
  30. Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation 2015;131:861-870. https://doi.org/10.1161/CIRCULATIONAHA.114.011201
  31. Emrich T, Emrich K, Abegunewardene N, et al. Cardiac MR enables diagnosis in 90% of patients with acute chest pain, elevated biomarkers and unobstructed coronary arteries. Br J Radiol 2015;88:20150025. https://doi.org/10.1259/bjr.20150025
  32. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636-2648. https://doi.org/10.1093/eurheartj/eht210
  33. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002;23:1177-1189. https://doi.org/10.1053/euhj.2001.3081
  34. Schiele F, Gale CP, Bonnefoy E, et al. Quality indicators for acute myocardial infarction: A position paper of the Acute Cardiovascular Care Association. Eur Heart J Acute Cardiovasc Care 2017;6:34-59. https://doi.org/10.1177/2048872616643053